Dianthus Therapeutics, Inc. /DE/

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

DNTH$88.81-1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share data)

Accumulated
Other · Total
Common Stock · Additional · Accumulated · Comprehensive · Stockholders’
	Shares	Amount	Paid-in Capital	Deficit	(Loss)/Income	Equity
Balance, December 31, 2025	43,223,090	$43	$829,598	$(336,729)	$489	$493,401
Issuance of common stock and pre-funded warrants in connection with public offering, net of issuance costs of $1,544	8,470,989	8	676,072	—	—	676,080
Issuance of common stock pursuant to at-the-market offering, net of issuance costs	1,123,126	1	58,730	—	—	58,731
Exercise of warrants and pre-funded warrants	1,004,580	1	—	—	—	1
Exercise of stock options (net of receivable for stock option proceeds in transit)	753,075	1	4,276	—	—	4,277
Issuance of common stock under employee stock purchase plan	7,889	—	120	—	—	120
Stock-based compensation expense	—	—	10,602	—	—	10,602
Net loss	—	—	—	(40,834)	—	(40,834)
Unrealized loss on marketable securities	—	—	—	—	(1,064)	(1,064)
Balance, March 31, 2026	54,582,749	$54	$1,579,398	$(377,563)	$(575)	$1,201,314
Exercise of stock options (net of receivable for stock option proceeds in transit)	215,589	1	10,580	—	—	10,581
Stock-based compensation expense	—	—	11,898	—	—	11,898
Net loss	—	—	—	(50,215)	—	(50,215)
Unrealized loss on marketable securities	—	—	—	—	(1,553)	(1,553)
Balance, June 30, 2026	54,798,338	$55	$1,601,876	$(427,778)	$(2,128)	$1,172,025
Issuance of common stock pursuant to at-the-market offering, net of issuance costs	1,005,700	1	98,065	—	—	98,066
Exercise of stock options	483,956	—	9,163	—	—	9,163
Issuance of common stock under employee stock purchase plan	7,232	—	244	—	—	244
Stock-based compensation expense	—	—	12,721	—	—	12,721
Net loss	—	—	—	(46,643)	—	(46,643)
Unrealized loss on marketable securities	—	—	—	—	(4,147)	(4,147)
Balance, September 30, 2026	56,295,226	$56	$1,722,069	$(474,421)	$(6,275)	$1,241,429
Balance, December 31, 2024	31,115,341	$31	$526,732	$(174,392)	$106	$352,477
Exercise of pre-funded warrants	1,000,333	1	—	—	—	1
Exercise of stock options	3,321	—	31	—	—	31
Issuance of common stock under employee stock purchase plan	6,938	—	129	—	—	129
Stock-based compensation expense	—	—	5,315	—	—	5,315
Net loss	—	—	—	(29,511)	—	(29,511)
Unrealized gain on marketable securities	—	—	—	—	164	164
Balance, March 31, 2025	32,125,933	$32	$532,207	$(203,903)	$270	$328,606
Exercise of stock options	50,549	—	568	—	—	568
Stock-based compensation expense	—	—	5,706	—	—	5,706
Net loss	—	—	—	(31,629)	—	(31,629)
Unrealized loss on marketable securities	—	—	—	—	(172)	(172)
Balance, June 30, 2025	32,176,482	$32	$538,481	$(235,532)	$98	$303,079
Issuance of common stock and pre-funded warrants in connection with public offering, net of issuance costs of $404	7,627,879	8	271,856	—	—	271,864
Exercise of pre-funded warrants	2,833,588	3	(3)	—	—	—
Exercise of stock options	204,751	—	2,229	—	—	2,229
Issuance of common stock under employee stock purchase plan	11,863	—	188	—	—	188
Stock-based compensation expense	—	—	5,794	—	—	5,794
Net loss	—	—	—	(36,765)	—	(36,765)
Unrealized gain on marketable securities	—	—	—	—	65	65
Balance, September 30, 2025	42,854,563	$43	$818,545	$(272,297)	$163	$546,454

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.